Table 1.
Demographics, physiological measurements, and medication use.
| Omega-3 “No” (n = 44) | Omega-3 “Yes” (n = 46) | All Participants (n = 90) | p | |
|---|---|---|---|---|
| Sex, n female [% female] | 33 [75%] | 29 [63%] | 62 [69%] | 0.221 |
| Age, years | 71.2 [4.6] | 70.5 [5.0] | 70.8 [4.8] | 0.335 |
| Education, years | 16.8 [2.7] | 16.6 [2.6] | 16.7 [2.6] | 0.738 |
| ASCVD Risk Score, % | 16.2 [10.3] | 15.8 [8.9] | 16.0 [9.5] | 0.837 |
| Body Mass Index, kg/m2 | 26.2 [4.3] | 27.4 [4.2] | 26.8 [4.3] | 0.083 |
| Amyloid-β (Aβ) Load, SUVR | 1.04 [0.17] | 1.02 [0.15] | 1.03 [0.16] | 0.994 |
| Target Exercising Watts | 58.3 [21.4] | 65.1 [21.9] | 61.8 [21.8] | 0.136 |
| Exercising PETCO2, mmHg | 38.2 [4.1] | 37.3 [4.2] | 37.7 [4.2] | 0.286 |
| Exercising MAP, mmHg | 105.7 [24.1] | 103.3 [15.8] | 104.5 [20.3] | 0.948 |
| ACE inhibitor use, n [%] | 3 [7%] | 6 [13%] | 9 [10%] | 0.486 |
| ARB use, n [%] | 6 [14%] | 8 [17%] | 14 [16%] | 0.623 |
| Beta-blocker use, n [%] | 6 [14%] | 6 [13%] | 12 [13%] | 0.934 |
| CCB use, n [%] | 4 [9%] | 7 [15%] | 11 [12%] | 0.375 |
| Thiazide use, n [%] | 1 [2%] | 1 [2%] | 2 [2%] | 1.000 |
| Statin use, n [%] | 17 [39%] | 23 [50%] | 40 [44%] | 0.278 |
Values are mean [standard deviation] unless otherwise noted. ASCVD Risk Score = atherosclerotic cardiovascular disease risk score; SUVR = standard uptake value ratio, arbitrary units; Exercising PETCO2 = average end-tidal carbon dioxide during exercise; Exercising MAP = average mean arterial pressure during exercise; ACE inhibitor = angiotensin-converting-enzyme inhibitor; ARB = angiotensin II receptor blocker; CCB = calcium channel blocker.